Interferon-α combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: A randomized controlled trial

Journal of Viral Hepatitis

Volumn 10, Issue 4, 2003, Pages 306-309

  Andreone, Pietro ^a,b   Gramenzi, A ^a   Cursaro, C ^a   Biselli, M ^a   Lorenzini, S ^a   Loggi, E ^a   Felline, F ^a   Fiorino, S ^a   Di Giammarino, L ^a   Porzio, F ^a   Galli, S ^b   Bernardi, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti HCV therapy; HCV; Interferon; Ketoprofen; NSAIDs

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; INTERFERON; KETOPROFEN; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THYROID DISEASE; VIRUS LOAD;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; KETOPROFEN; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038383547     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00449.x     Document Type: Article

References (16)

1. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
2. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
3. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
4. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
5. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
6. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
8. Hannigan GE, Williams BRG. Signal transduction by interferon-a through arachidonic acid metabolism. Science 1991; 251: 204-207.
9. Baskin G. Interferon signalling through arachidonic acid-dependent pathway: a clue to adjuvant therapy for chronic viral hepatitis? Hepatology 1991, 14: 392-394.
10. Andreone P, Cursaro C, Gramenzi A et al. Indomethacin enhances serum 2′,5′-oligoadenylate synthetase in patients with hepatitis B an C virus chronic active hepatitis. J Hepatol 1994; 21: 984-988.
11. Giambartolomei S, Artini M, Almerighi C, Moavero SM, Leveremo M, Balsano C. Non-steroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phospholryulation. Hepatology 1999; 30: 510-516.
12. Andreone P, Cursaro C, Gramenzi A et al. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study. ItaI J Gastroenterol Hepatol 1999; 31: 688-694.
13. Munoz AE, Levi D, Podestà A et al. Interferon-α2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and rondomized trial. Gut 2000; 46: 427-431
14. Fabris P, Tositti G, Negro F et al. Interferon alfa-2b alone or in combination with ketoprofen as teratment for interferon-na chronic hepatotits C patients. Aliment Pharmacol Ther 1999; 13: 1329-1334.
15. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
16. Zarski JP, Maynard-Muet M, Chousterman S et al. Tenoxicam, a non-steroidal anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998; 27: 862-867.